{"id":37863,"date":"2017-02-22T07:52:04","date_gmt":"2017-02-22T12:52:04","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37863"},"modified":"2017-02-22T07:52:04","modified_gmt":"2017-02-22T12:52:04","slug":"trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863","title":{"rendered":"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Trevena Inc (NASDAQ:TRVN)<\/strong> reported positive top-line report from its Phase III APOLLO-2 and APOLLO-1 pivotal efficacy trials of oliceridine in acute pain following abdominoplasty and bunionectomy, respectively. In both trials, all dose regimens recorded their primary objective of statistically greater analgesic effectiveness than placebo, as noted by responder rate.<\/p>\n<p style=\"text-align: justify;\">Moreover, oliceridine demonstrated dose-related trends of progresses versus morphine on different measures of gastrointestinal tolerability and respiratory safety, both major unmet areas in acute pain management.<\/p>\n<h2 style=\"text-align: justify;\"><strong>The buzz<\/strong><\/h2>\n<p style=\"text-align: justify;\">Maxine Gowen, Ph.D., the Chief Executive Officer of Trevena, reported that they consider the report for all 3 dose plans will advance FDA nod of IV oliceridine with an extensive indication of management of acute pain. \u00a0These successful studies cap a development plan that has shown steady differentiation of oliceridine from morphine in numerous clinical trials. The management look forward to filing a new drug application with an objective of bringing this unique product to patients.<\/p>\n<p style=\"text-align: justify;\">Timothy Beard, M.D. reported that this report is exciting. It validates earlier report and demonstrate an improved tolerability and safety profile of oliceridine against morphine, with similar data across the two trials.<\/p>\n<p style=\"text-align: justify;\">Both APOLLO studies were Phase 3, randomized, multicenter, placebo- and active-controlled and double-blind trials of oliceridine. The main objective of each trial was to assess the analgesic efficacy of oliceridine as against placebo. Secondary objectives comprised comparisons of safety, tolerability and efficacy of oliceridine to morphine.<\/p>\n<p style=\"text-align: justify;\">Both trials comprised numerous measurements of vomiting and nausea, which occur in almost 30% of postoperative people and increase expenses to hospitals, as well as numerous measures of respiratory safety, which can result in grave and expensive risks to patient safety.<\/p>\n<p style=\"text-align: justify;\">In the last trading session, the stock price of Trevena declined more than 40% to close the day at $4.27. After the recent decline, the market cap of company stands at $226.65 million.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trevena Inc (NASDAQ:TRVN) reported positive top-line report from its Phase III APOLLO-2 and APOLLO-1 pivotal efficacy trials of oliceridine in acute pain following abdominoplasty and [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":37864,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[12316,5983,10507,5982],"stock_ticker":[],"class_list":["post-37863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-maxine-gowen","tag-nasdaqtrvn","tag-trevena-inc","tag-trevena-inc-nasdaqtrvn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Trevena Inc (NASDAQ:TRVN) reported positive top-line report from its Phase III APOLLO-2 and APOLLO-1 pivotal efficacy trials of oliceridine in acute pain following abdominoplasty and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-22T12:52:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"294\" \/>\n\t<meta property=\"og:image:height\" content=\"171\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine\",\"datePublished\":\"2017-02-22T12:52:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg\",\"keywords\":[\"Maxine Gowen\",\"NASDAQ:TRVN\",\"Trevena Inc.\",\"Trevena Inc. (NASDAQ:TRVN)\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\",\"name\":\"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg\",\"datePublished\":\"2017-02-22T12:52:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg\",\"width\":294,\"height\":171,\"caption\":\"Trevena Inc\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863","og_locale":"en_US","og_type":"article","og_title":"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine - Wall Street PR","og_description":"Trevena Inc (NASDAQ:TRVN) reported positive top-line report from its Phase III APOLLO-2 and APOLLO-1 pivotal efficacy trials of oliceridine in acute pain following abdominoplasty and [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-02-22T12:52:04+00:00","og_image":[{"width":294,"height":171,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine","datePublished":"2017-02-22T12:52:04+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg","keywords":["Maxine Gowen","NASDAQ:TRVN","Trevena Inc.","Trevena Inc. (NASDAQ:TRVN)"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863","url":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863","name":"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg","datePublished":"2017-02-22T12:52:04+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/02\/Trevena-Inc.jpg","width":294,"height":171,"caption":"Trevena Inc"},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/trevena-inc-nasdaqtrvn-releases-positive-report-from-phase-iii-pivotal-efficacy-trials-of-intravenous-oliceridine-37863#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Trevena Inc (NASDAQ:TRVN) Releases Positive Report From Phase III Pivotal Efficacy Trials Of Intravenous Oliceridine"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37863"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37863\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37864"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37863"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}